⚠ STRICT REGULATORY DIRECTIVE: B2B BIOLOGICAL API SUPPLY ONLY

Shaanxi Sunrise Pharmaceutical Co., Ltd. operates strictly as an industrial biological raw material supplier. The Pembrolizumab API (CAS: 1374853-91-4) discussed below is intended exclusively for biopharmaceutical R&D, in-vitro assay development, in-vivo animal modeling, and biosimilar scale-up. It is NOT a finished clinical drug product and is strictly prohibited for direct human or veterinary therapeutic administration.

In the landscape of modern oncology, immune checkpoint inhibitors have shifted from experimental novelties to the foundational backbone of cancer therapeutic protocols. Pembrolizumab API is a highly engineered, humanized monoclonal antibody targeting the Programmed Death Receptor-1 (PD-1). For procurement directors and R&D scientists, it is not merely a reagent; it is a high-value biological asset that dictates the success of multimillion-dollar preclinical trials and biosimilar pipelines.

At Shaanxi Sunrise, we do not tolerate biological degradation or lot-to-lot structural variance. When you procure monoclonal antibody raw materials from our facilities, you are securing a biochemically stable, low-endotoxin macro-molecule designed to withstand the rigorous demands of advanced biopharmaceutical engineering.

The molecular brilliance of Pembrolizumab is not just what it binds to, but what it actively avoids doing. Tumor cells express PD-L1 ligands that bind to PD-1 receptors on T-cells, delivering an inhibitory "brake" signal. Pembrolizumab specifically sterically hinders this interaction, reactivating the cytotoxic T-lymphocytes.

However, generic formulators often overlook the isotype design. Pembrolizumab is specifically engineered as an IgG4 kappa isotype containing an S228P mutation in the Fc region. Why? Because an IgG1 isotype would trigger Antibody-Dependent Cellular Cytotoxicity (ADCC) and Complement-Dependent Cytotoxicity (CDC), effectively instructing the immune system to destroy the very T-cells the drug is trying to save. The S228P mutation stabilizes the hinge region, preventing Fab-arm exchange. For laboratories developing companion diagnostics or performing ELISA binding assays, securing an API with intact, perfectly folded IgG4 structures is non-negotiable.

Clinical efficacy is directly tied to the Tumor Proportion Score (TPS) for PD-L1 expression. However, in the R&D lab, therapeutic prediction requires flawless binding kinetics. Substandard biological raw materials suffer from compromised Complementarity-Determining Regions (CDRs) due to improper lyophilization or aggressive buffering.

"If your API exhibits compromised Surface Plasmon Resonance (SPR) parameters or elevated dissociation constants (Kd), your entire pre-clinical NSCLC or melanoma data set is fundamentally flawed."

Shaanxi Sunrise guarantees exceptional binding affinity. We supply research-grade and pharmaceutical-grade Pembrolizumab powder that maintains absolute structural integrity, allowing your R&D teams to accurately model TPS thresholds and predict clinical responses without analytical background noise.

Monotherapy is effective, but multi-mechanism "Combination Therapy" is driving modern oncology. Researchers are aggressively pairing Pembrolizumab with anti-angiogenic TKIs (like Lenvatinib) or cytotoxic chemotherapies for advanced renal cell carcinoma. This "1+1 > 2" clinical strategy presents a massive biochemical challenge for formulation scientists: protein stability.

When you mix biologicals with harsh small-molecule environments, monoclonal antibodies tend to aggregate or unfold. Our Pembrolizumab API is engineered for extreme matrix compatibility. Whether you are developing novel L-histidine buffers, introducing polysorbate 80, or engineering lipid nanoparticle co-delivery systems, our API resists shear stress and aggregation, streamlining your multi-drug stability testing.

The FDA approval of Pembrolizumab for Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors shattered traditional anatomical oncology. It proved that the genetic biomarker is more critical than the organ of origin. For pharmaceutical procurement, this "one drug for many diseases" model exponentially increases the academic and commercial value of high-purity Pembrolizumab API.

Universities and biopharma labs require massive volumes of stable Pembrolizumab to run comprehensive pan-tumor xenograft models. Shaanxi Sunrise provides scalable batch sizes to support massive tissue-agnostic screening programs without lot-to-lot variation.

Immune-Related Adverse Events (irAEs), such as severe pneumonitis or colitis, are inherent risks of immune checkpoint blockade. However, in a laboratory setting, you must isolate the drug's true mechanism from impurity-induced inflammation.

The biopharma industry is pivoting away from lengthy intravenous (IV) infusions toward rapid Subcutaneous (SC) injections. Achieving an SC formulation requires packing monoclonal antibodies at extremely high concentrations (often > 100 mg/mL). At these densities, viscosity spikes exponentially, making the fluid unsyringeable.

Formulators are exploring co-formulations with recombinant human hyaluronidase (rHuPH20) to temporarily degrade the subcutaneous extracellular matrix. To succeed in this cutting-edge R&D, you need an API that maintains conformational stability at ultra-high concentrations without precipitating. Our high-concentration-ready Pembrolizumab API empowers formulation engineers to solve the viscosity equation.

As patent cliffs approach and the biosimilar market enters a white-hot phase, relying on unverified biological raw materials is a terminal mistake. At Shaanxi Sunrise, we operate under rigorous ISO and GMP-aligned quality systems. We do not just provide an antibody; we provide the exact proteomic consistency required to advance your immunotherapeutic pipelines.

Require flawless biochemical parameters? Contact the Shaanxi Sunrise technical team today to secure high-purity Pembrolizumab API (CAS 1374853-91-4) and audit our comprehensive analytical data packages (SEC-HPLC, cIEF, Endotoxin).

• FDA Database: KEYTRUDA (pembrolizumab) Full Prescribing Information & BLA Documentation.

• National Cancer Institute (NCI): PD-1 and PD-L1 Inhibitors Clinical Efficacy.

• Nature Reviews Clinical Oncology: The Future of Immune Checkpoint Therapy and Isotype Engineering.

• The Lancet: Pembrolizumab versus Chemotherapy for PD-L1-positive NSCLC.